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of published randomized controlled trials
Xue-Hui Liu1,3, Chun-Yan Xu2 and Guang-Hui Fan1*Abstract
Background: Atrial fibrillation is a common complication after cardiac surgery. The aim of this study is to evaluate
whether N-acetylcysteine (NAC) could prevent postoperative atrial fibrillation (POAF).
Methods: PubMed, Embase and Cochrane Center Register of Controlled Trials were searched from the date of their
inception to 1 July 2013 for relevant randomized controlled trials (RCTs), in which NAC was compared with controls
for adult patients undergoing cardiac surgery. Outcome measures comprised the incidence of POAF, all-cause
mortality, length of intensive care unit (ICU) stay, hospital length of stay, and the incidence of cerebrovascular
events. The meta-analysis was performed with the fixed-effect model or random-effect model according to the
heterogeneity.
Results: We retrieved ten studies enrolling a total of 1026 patients. Prophylactic NAC reduced the incidence of
POAF (OR 0.56; 95% CI 0.40 to 0.77; P < 0.001) and all-cause mortality (OR 0.40; 95% CI 0.17 to 0.93; P = 0.03)
compared with controls, but failed to reduce the stay in ICU and overall stay in hospital. No difference in the
incidence of cerebrovascular events was observed.
Conclusions: Prophylactic use of NAC could reduce the incidence of POAF and all-cause mortality in adult patients
undergoing cardiac surgery. However, larger RCTs evaluating these and other postoperative complication endpoints
are needed.
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Atrial fibrillation (AF) is a common complication that
occurs after cardiac surgery. The incidence of postopera-
tive atrial fibrillation (POAF) ranges from 10% to 65%
depending on the type of surgery, perioperative charac-
teristics, methods of monitoring and the definition of AF
[1,2]. Previous studies [2-7] indicated that AF is associated
with prolonged length of hospital stay, risk of stroke, and
mortality, thus extensive research has been conducted to
explore the mechanism of POAF and identify the effective
method for preventing POAF. Beta-blockers and amio-
darone are used widely to minimize the risk of POAF
and recommended by current guidelines [8]. However,* Correspondence: fanguanghui59@163.com
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related side effects. Clinical studies have demonstrated
higher inflammatory cytokines level and oxidative dam-
age in patients who developed POAF versus those who
did not after undergoing cardiac surgery, suggesting that
oxidative stress and inflammatory reaction contribute to
POAF [9-11].
N-acetylcysteine (NAC) is an antioxidant and anti-
inflammatory agent, and could reduce cellular oxidative
damage and systematic inflammation during cardiac
surgery [12,13]. Previous meta-analyses showed that the
NAC supplementation effectively reduced the incidence
of POAF [14,15]. However, of all the included studies,
only one [12] treated POAF as primary endpoint and
showed a positive result. Recently, a large trial demon-
strated that there was no statistical difference in the in-
cidence of POAF between the NAC and placebo groupsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow diagram of trials included in the meta-analysis.
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http://www.biomedcentral.com/1471-2261/14/52[16]. Thus, we conducted an updated meta-analysis to
further evaluate the efficacy of NAC on the prevention
of POAF in adult patients undergoing cardiac surgery.
Besides, we also assessed whether NAC could reduce
hospital length of stay, intensive care unit (ICU) stay,
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Literature search
A comprehensive search was performed to identify all
published randomized controlled trials (RCTs) of NAC
versus control during cardiac surgery in any language.
PubMed, Embase and Cochrane Central Register of Con-
trolled Trials databases were searched from the date of
their inception to 1 July 2013. Searched terms included N-
acetylcysteine, acetylcysteine, acetadote, mucomyst, heart
surgery, cardiac surgery, cardiothoracic surgery, cardiopul-
monary bypass, CPB, coronary artery bypass graft, CABG,
valve surgery, valvular surgery and atrial fibrillation.
Inclusion and exclusion criteria
Only RCTs reporting the use of NAC in the prevention
of POAF were included in the meta-analysis (including
those reporting the concomitant use of other anti-
arrhythmic agents). Exclusion criteria included: (1) du-
plicated data; (2) laboratory study; (3) abstract, review
or letter to editor; and (4) patient age less than 18 years.
Based on these criteria, two investigators (Liu and Xu)Medical history Previous medication
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DM, Hypertension BRB, CCB, ACEI, Diuretics
RB, beta-receptor blocker; CAD, coronary artery disease; CCB, calcium channel
ure; SD, standard deviation; DM, diabetes mellitus; CVD, cerebrovascular
ase.
Table 2 Outcomes of included studies in the meta-analysis
Reference POAF Duration of ICU (hours) Hospitalization (days) Mortality Nonfatal CBV
NAC Control NAC Control NAC Control NAC Control NAC Control
Ozaydin 2008 [12] 3/58 12/57 NA NA 7.7 ± 3 7.9 ± 4.2 0/58 2/57 1/58 0/57
Kazemi 2013 [16] 14/120 19/120 120 ± 45.6 115.2 ± 79.2 7.4 ± 1.3 7.2 ± 0.9 1/120 2/120 1/120 1/120
Eren 2003 [19] 2/10 1/10 NA NA NA NA 0/10 0/10 0/10 0/10
Orhan 2006 [20] 0/10 1/10 23.2 ± 1.75 22.6 ± 1.84 7.2 ± 0.42 7.3 ± 0.48 0/10 0/10 NA NA
Ozaydin 2013 [21] 9/104 25/104 NA NA NA NA 1/104 2/104 2/104 0/104
Peker 2008 [22] 0/19 2/21 NA NA NA NA 0/19 0/21 0/19 0/21
Wijeysundera 2007 [23] 50/88 58/87 45.6 40.8* 8 (6–12) 8 (6–12)† 0/88 7/87 4/88 4/87
EI-Hamamsy 2007 [24] 4/50 6/50 NA NA 5.4 ± 2.3 5.3 ± 2.5 3/50 0/50 0/50 0/50
Haase 2007 [25] 19/30 16/30 44 45* 8(7–11) 8(7–11)† 0/30 1/30 NA NA
Kim 2011 [26] 4/24 8/24 72 ± 36 81.6 ± 50.4 11.3 ± 6.3 10.5 ± 4.5 0/24 2/24 0/24 0/24
Data are number or mean ± deviation; CBV, cerebrovascular events; NA, data not available; *values expressed as median; †data expressed as median
(interquartile range).
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reading title and/or abstract of all identified literatures.
All potential eligible studies were obtained for further
assessment.Data extraction
Two investigators (Liu and Xu) independently extracted
the following information from each article: first author’s
name, year of publication, country of origin, surgery type,
perioperative characteristics, NAC protocol, incidence of
POAF, length of ICU and hospital stay, all-cause mortality
and cerebrovascular events. The primary outcome was the
incidence of POAF. The length of hospital and ICU stay,
all-cause mortality, and the incidence of cerebrovascularTable 3 POAF outcome definition and assessment
Reference Method of atrial fibrillation assessment
Ozaydin 2008 [12] ECGs performed continuously at the first 2 posto
in the ICU, and 2 times a day routinely when new
developed or observed in the wards.
Kazemi 2013 [16] Holter performed continuously for 72 h after surg
Eren 2003 [19] ECGs were recorded on the first postoperative da
Orhan 2006 [20] Not reported
Ozaydin 2013 [21] ECGs performed continuously during ICU stay an
was used during the rest of hospitalization.
Peker 2008 [22] ECGs conducted continuously during the first 2 p
in the ICU, and 2 times per day routinely when n
developed or noted
Wijeysundera 2007 [23] Continuous telemetry or 12-lead ECGs
EI-Hamamsy 2007 [24] Not reported
Haase 2007 [25] Not reported
Kim 2011 [26] Not reported
ECG, electrocardiogram.events were considered secondary outcomes. Disagree-
ments were resolved by consensus.Quality assessment
The methodological quality of the studies included in
the meta-analysis was assessed using validated Jadad 5
point scale [17]. This system emphasizes on the follow-
ing three parts when defining the quality of a RCT:
(1) randomization; (2) blinding; and (3) description of
withdrawals and dropouts. A score of one is given for
each of the points described. A further point is obtained
where the method of randomization and/or blinding is
given and is appropriate; where it is inappropriate, a point
is deducted. Studies with a score ≤ 2 were considered lowDefinition of atrial fibrillation
perative days
symptom
An irregular narrow complex rhythm with absence
of discrete p-waves lasting longer than 5 minutes
ery More than 5 minutes of AF or associated with
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Figure 2 Effects of N-acetylcysteine on the prevention of postoperative atrial fibrillation.
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quality.
Statistical analysis
Outcomes were treated as dichotomous (when incidence
was reported) or continuous (when the mean and stand-
ard deviation were reported) variables. For dichotomous
variables, odds ratios (ORs) and 95% confidence inter-
vals (CIs) were calculated. For continuous variables, the
weighted mean difference (WMD) was calculated. Het-
erogeneity was explored using I2, which describes the
percentage of total variation across trials due to hetero-
geneity rather than chance alone. When I2 was more
than 50%, significant statistical heterogeneity was con-
sidered to be present [18]. Pooled estimates of efficacy
were calculated using the fixed-effects model. If there
was heterogeneity, the random-effects model was used.
Sensitivity analyses were conducted to test the robust-
ness of overall pooled effect. The presence of publication
bias was evaluated by using funnel plot. A two-tailed P-
value < 0.05 was considered as significant difference. All
statistical analyses were performed using Review Man-
ager version 5.2.
Results
Identification of eligible studies
One hundred and fifteen articles were identified by the
initial literature search, and 90 studies were excludedFigure 3 Effects of long-term N-acetylcysteine administration on theafter title and abstract screening. Therefore, 25 potential
relevant studies were retrieved to read the entire manu-
script. Fifteen studies were further excluded because
they did not treat POAF as an outcome. Consequently,
10 trials (n = 1026 patients) were included in this meta-
analysis (Figure 1).
Characteristics of eligible studies
Patients’ characteristics of the included studies are
shown in Table 1. The number of patients ranged from
20 [19,20] to 240 [16]. Of the 10 RCTs, five trials were
conducted in Turkey [12,19-22], two in Canada [23,24],
one in Iran [16], one in Germany [25], and one in Korea
[26]. With the use of Jadad 5 point score, all studies
were considered high quality. Both male and female
were included in all trials. Only one study [25] included
some patients with a history of AF. Diabetic mellitus,
hypertension, chronic heart failure, and coronary artery
disease were the major concomitant diseases. Five
trials [19,20,22,24,26] enrolled 228 patients undergoing
CABG only, and the remaining 5 trials [12,16,21,23,25]
included 798 patients undergoing valve surgery or com-
bination valve surgery with CABG. NAC administration
regimen is also presented in detail in Table 1, with 8
studies [12,19-23,25,26] using intravenous administra-
tion and 2 studies [16,24] using oral administration
before cardiac surgery. The duration of NAC adminis-
tration after cardiac surgery varied from 4 hours [23] toprevention of postoperative atrial fibrillation.
Figure 4 Effects of short-term N-acetylcysteine administration on the prevention of postoperative atrial fibrillation.
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cacy of beta-blocker (carvedilol) with NAC on the pre-
vention of POAF.
Incidence of POAF
The data of the included studies are shown in Table 2.
The method of monitoring and the definition of POAF
are presented in Table 3. Of the 10 trials, only four
[12,16,21] treated POAF as their primary endpoint.
Pooling all ten RCTs, 20.5% (105 of 513) of patients
given NAC and 28.8% (148/513) of controls developed
POAF. The meta-analysis of ten trials using a fixed-effects
model showed that NAC reduced the incidence of POAF
(OR 0.56, 95% CI 0.40 to 0.77; P < 0.001; Figure 2) com-
pared with controls, with no heterogeneity between the
studies (I2 = 15%, P = 0.31).
Sensitivity analyses were conducted to test the robust-
ness of the main analysis. We tested whether excluding
small sample studies (n <60 patients) [19,20,22,26] would
change the direction of the overall result. The meta-
analysis of the remaining studies (OR 0.57, 95% CI 0.40 to
0.80; P = 0.001) [12,16,21,23-25] was similar to the overall
result, with little statistical heterogeneity (I2 = 42%, P =
0.12). A trial [25] enrolled some patients with a history of
AF, but the pooled results (OR 0.50; 95% CI 0.35 to 0.71;
P < 0.001; I2 = 0%, Pheterogeneity = 0.56) did not change when
this trial was exclude. In addition, we tested whether
different duration of NAC supplementation after cardiac
surgery would alter the direction of the overall result.
Using the fixed-effects model, the meta-analysis of stud-
ies (OR 0.40; 95% CI 0.25 to 0.65; P < 0.001; I2 = 22%,
Pheterogeneity =0.28; Figure 3) [12,16,21,22] with a long-
term (lasting for 48 h-72 h after operation) was similarFigure 5 Effects of N-acetylcysteine on the length of hospital stay.to the overall effects (OR 0.56, 95% CI 0.40 to 0.77).
However, it failed to reduce the incidence of POAF with
a short-term NAC (within 24 h after surgery) supple-
mentation (OR 0.64; 95% CI 0.39 to 1.06; P = 0.09; I2 =
0%, Pheterogeneity =0.7; Figure 4) [19,23-26].
Length of ICU stay
Five studies [16,20,23,25,26] reported the data of ICU
length of stay, while only three [16,20,26] studies re-
ported the values as mean ± standard deviation. All the
data were converted from days into hours for analysis.
Prophylactic NAC was not associated with a reduction
in ICU length of stay (WMD 0.60; 95% CI −0.97 to 2.16;
P = 0.45). No heterogeneity of included studies was
noted (I2 = 0%, P = 0.64).
Hospital length of stay
Five [12,16,20,24,26] studies reported values as mean ±
standard deviation, two [23,25] expressed data as median
and interquartile range, and one [21] showed values by
bar graph. The meta-analysis of the five studies using a
fixed-effects model presented that NAC treatment did
not reduce the length of hospital stay (WMD 0.09; 95%
CI −0.13 to 0.31; P = 0.40; Figure 5). No statistical het-
erogeneity was observed across studies (I2 = 0%, P =
0.76).
All-cause mortality
Death occurred in 5 of 513 patients (0.9%) treated with
NAC and in 16 of 513 patients (3.1%) treated with pla-
cebo. Use of NAC was associated with a reduction in all-
cause death (OR 0.40; 95% CI 0.17 to 0.93; P = 0.03; I2 =
0%, Pheterogeneity =0.44; Figure 6).
Figure 6 Effects of N-acetylcysteine on the all-cause mortality.
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Seven [12,16,19,21-23,26] studies reported the incidence
of cerebrovascular events after operation. Cerebrovascu-
lar events occurred in 8 of 423 patients (1.9%) treated
with NAC and in 5 of 424 patients (1.2%) treated with
placebo. Prophylactic use of NAC failed to present a re-
duction in cerebrovascular accidents (OR 1.68; 95% CI
0.60 to 4.69; P = 0.32; I2 = 0%, Pheterogeneity =0.64).
Publication bias
The funnel plot for the incidence of POAF was shown in
Figure 7. The funnel plot appeared symmetrical, suggest-
ing that there was no potential publication bias among
the included trials.
Discussion
This meta-analysis shows that prophylactic NAC can re-
duce the incidence of POAF in adult patients undergoing
cardiac surgery, with a conclusion similar to the previous
meta-analyses [14,15]. However, the meta-analysis of trials
(OR 0.64; 95% CI 0.39 to 1.06) using a short-term NAC
administration, differing from the pooled effect of studies
with a long-term (OR 0.51; 95% CI 0.33 to 0.79), demon-
strates that there is no significant difference comparedFigure 7 Funnel plot of N-acetylcysteine on the prevention of
atrial fibrillation after cardiac surgery.with controls. These findings suggest that NAC can be
used for adult patients undergoing cardiac surgery to pre-
vent POAF. It would be more reasonable to prolong the
duration of NAC administration up to postoperative day
2–3. Previous studies presented that on postoperative day
2–3 the inflammatory cytokines levels are the highest, cor-
responding to the day of the highest incidence of POAF
[7,27]. To some extent, the different results between
short-term and long-term NAC administration may be
associated with the anti-inflammatory property of NAC.
Additionally, NAC has a generally good safety profile
[16,21,23]. Of the 10 included studies, only one [23] re-
ported evident side effects among patients, but there
was no statistical difference when compared with con-
trol group.
An increasing body of evidence demonstrates that oxi-
dative stress and inflammatory reaction play an important
role in the pathophysiology of POAF [7,9,28]. Antioxi-
dants, including NAC, have proved to decrease serum
levels of molecules markers of cellular oxidative stress in
patients undergoing heart surgery [9-11,16,28,29]. NAC is
a glutathione precursor, by entering cells and being hydro-
lyzed to cysteine, it stimulates glutathione synthesis
[12,16]. In this way, it increases the level of intracellular
reduced glutathione, which is often depleted as a response
to increased status of inflammation reaction and oxidative
stress [16,30]. In addition to that, it may also block renin
angiotensin system and/or atrial remodeling via its anti-
oxidant actions and anti-inflammatory [12,20,31]. Thus,
NAC is a potential agent used for reducing the incidence
of POAF in adult patients undergoing cardiac surgery.
Although POAF is often considered both transient and
self-limiting [7,15], it can increase the length of ICU and
hospital stay, cerebrovascular events, and mortality [3-7].
With regard to ICU and hospital stay, the pooled effects
are similar to the pre-existing meta-analyses [13-15],
showing no significant difference compared with controls.
There is also no significant reduction in the risk of cere-
brovascular events (OR 1.68; 95% CI 0.60 to 4.69) between
two groups. This meta-analysis, however, demonstrates
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of all-cause mortality (OR 0.40; 95% CI 0.17 to 0.93),
which differs from the previous meta-analysis (OR 0.81;
95% CI 0.39 to 1.68) conducted by Wang et al. [13].
There are several limitations to this meta-analysis that
should be noted. First, there is significant heterogeneity
in both the methods of monitoring and the definition of
POAF between the studies. AF following cardiac surgery
was reported as a clinical outcome in seven studies
[19,20,22-26], and only three studies [12,16,21] treated
POAF as a primary endpoint. All these may lead to po-
tential overestimation or underestimation of the true in-
cidence of POAF. Second, for the POAF endpoint, the
use of beta-blockers and amiodarone was not the standard
therapy among most included studies [12,16,19,20,22-26].
Meanwhile, the adjunctive use of NAC in addition to
these proven prophylactic strategies is not known. An ad-
junctive prophylactic protocol, however, that might further
prevent POAF without reducing blood prssure and/or
heart rate. As such, Ozaydin and his colleagues demon-
strated that carvedilol plus NAC significantly reduced the
incidence of POAF compared with carvedilol plus placebo
[21]. Next, due to different NAC doses and schedules used
in these trials, we are unable to evaluate this heterogeneity
on clinical outcomes and identify an optimal NAC dose
from this meta-analysis. Finally, the positive effect seen is
based almost entirely on two trials from the same group
[12,21], however, the results of which have not been re-
produced in the majority of the other trials.
Future studies should aim to treat the incidence of
POAF as a primary endpoint, and standardize the defin-
ition of POAF. In addition, these studies should compare
various does of NAC, including varying lengths of ther-
apy. It is also important to assess the impact of NAC
supplementation on the top of already proven agents for
preventing POAF, including beta-blockers, amiodarone,
and any other potential prophylaxis.
Conclusions
This meta-analysis shows that prophylactic use of NAC
could reduce the incidence of POAF and all-cause mortal-
ity for adult patients undergoing cardiac surgery. However,
larger RCTs evaluating these and other postoperative
complication endpoints are needed.
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